Publication
KMT2C mediates the estrogen dependence of breast cancer through regulation of ERα enhancer function.
Authors not recorded
Oncogene2018PMID 29755131PMC6107480stubpubmedProvenance
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
No abstract stored. Read on PubMed
Linked entities
Linked entities (4)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 4
- cancerMalignant Breast Neoplasmcivic_curation1.00
- drugAromatase Inhibitorcivic_curation1.00
- geneKMT2Ccivic_curation1.00
- variantKMT2C Losscivic_curation1.00
Curated evidence
Evidence citing this paper (1)
civicProvenance
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 29755131
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| KMT2C Loss1 | ||||||||
| Aromatase Inhibitor | Malignant Breast Neoplasm | Predictive | B | Supports Resistance | 3 | accepted | EID6484In the 746 metastatic breast tumors analyzed,KMT2C mutations were found in 9.8% of tumors, making it one of the most commonly mutated genes in breast cancer. Analysis of the 818 cases in the TCGA data… (full text at CIViC) PMID 29755131 · Gala et al., 2018 · Open in CIViC | civic |